-
Sector Analysis
Respiratory Syncytial Virus (RSV) - Forecast in Asia-Pacific Markets to 2028
Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense RNA orthopneumovirus belonging to the family of Pneumoviridae. The virus was discovered in 1956, first as an isolate from a laboratory chimpanzee displaying symptoms of the common cold, and later from infants suffering from respiratory disease. The most common clinical scenario for RSV is an upper respiratory tract infection which is typically mild and self-limiting. However, RSV is the leading cause of lower respiratory tract infections (LRTIs) in infants, with...
-
Sector Analysis
Respiratory Syncytial Virus - Epidemiology Forecast to 2028
Respiratory syncytial virus (RSV) is a common respiratory infection that most children will be infected with by the time they are two years old. In healthy individuals RSV usually self-resolves within a week or two without need for significant therapeutic intervention. In preterm and very young infants, the elderly, or those with otherwise compromised immune systems, however, RSV can cause severe illness or death. It has been estimated that up to 30 million episodes of RSV-related lower respiratory infection occur...
-
Sector Analysis
Severe Sepsis and Septic Shock - Epidemiology Forecast to 2030
The burden of diagnosed incident cases of severe sepsis is expected to increase at an annual growth rate (AGR) of 2%, from around 2.3 million cases in 2020 to 2.8 million in 2030 in the seven major markets (7MM*). This report reveals that the increase is partly attributed to the moderately rising trend in incidence in the 7MM, combined with underlying demographic changes in the respective markets. Bishal Bhandari, PhD, Senior Epidemiologist at GlobalData, comments: “There will be an increasing trend...
-
Sector Analysis
Respiratory Syncytial Virus - Epidemiology Forecast to 2030
The Respiratory Syncytial Virus (RSV) prophylactic population in the eight major markets (*8MM) is projected to increase from over 14.55 million cases in 2020 to 15.64 million in 2030, with an annual growth rate (AGR) of 0.75%. This report estimates that in 2030, the US will have the highest number of prophylactic eligible individuals across the 8MM, with over 6.53 million individuals. Spain will have the lowest number of prophylactic eligible individuals with approximately 0.66 million individuals. In the *5EU,...
-
Product Insights
Onychomycosis (Tinea Unguium) - Global Clinical Trials Review, H2, 2021
GlobalData's clinical trial report, “Onychomycosis (Tinea Unguium) - Global Clinical Trials Review, H2, 2021" provides an overview of Onychomycosis (Tinea Unguium) Clinical trials scenario. This report provides top line data relating to the clinical trials on Onychomycosis (Tinea Unguium). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type....
-
Product Insights
Staphylococcal Infections - Global Clinical Trials Review, H2, 2021
GlobalData's clinical trial report, “Staphylococcal Infections - Global Clinical Trials Review, H2, 2021" provides an overview of Staphylococcal Infections Clinical trials scenario. This report provides top line data relating to the clinical trials on Staphylococcal Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides...
-
Product Insights
Epstein-Barr Virus (HHV-4) Infections - Global Clinical Trials Review, H2, 2021
GlobalData's clinical trial report, “Epstein-Barr Virus (HHV-4) Infections - Global Clinical Trials Review, H2, 2021" provides an overview of Epstein-Barr Virus (HHV-4) Infections Clinical trials scenario. This report provides top line data relating to the clinical trials on Epstein-Barr Virus (HHV-4) Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status...
-
Product Insights
Pandemic Influenza - Global Clinical Trials Review, H2, 2021
GlobalData's clinical trial report, “Pandemic Influenza - Global Clinical Trials Review, H2, 2021" provides an overview of Pandemic Influenza Clinical trials scenario. This report provides top line data relating to the clinical trials on Pandemic Influenza. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides...
-
Product Insights
Mumps - Global Clinical Trials Review, H2, 2021
GlobalData's clinical trial report, “Mumps - Global Clinical Trials Review, H2, 2021" provides an overview of Mumps Clinical trials scenario. This report provides top line data relating to the clinical trials on Mumps. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for...
-
Product Insights
Coronavirus Disease 2019 (COVID-19) - Global Clinical Trials Review, H2, 2021
GlobalData's clinical trial report, “Coronavirus Disease 2019 (COVID-19) - Global Clinical Trials Review, H2, 2021" provides an overview of Coronavirus Disease 2019 (COVID-19) Clinical trials scenario. This report provides top line data relating to the clinical trials on Coronavirus Disease 2019 (COVID-19) . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.